Clinical trials
Completed Observational Thrombocythemia, Essential trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Icahn School of Medicine at Mount Sinai | 4 |
| Shire | 4 |
| University Hospital, Bordeaux | 2 |
| Dr Yan Beauverd | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 1 |
| Federico II University | 1 |
| Incyte Corporation | 1 |
| National Institutes of Health Clinical Center (CC) | 1 |
| Queen's University, Belfast | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Thrombocythemia, Essential | 22 |
| Polycythemia Vera | 15 |
| Myeloproliferative Disorders | 11 |
| Primary Myelofibrosis | 11 |
| Blast Crisis | 2 |
| Burkitt Lymphoma | 2 |
| Immunoblastic Lymphadenopathy | 2 |
| Immunoglobulin Light-chain Amyloidosis | 2 |
| Intraocular Lymphoma | 2 |
| Leukemia, Biphenotypic, Acute | 2 |
Trials
Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.